Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIP2602 in Erectile Dysfunction Patients
NCT07899073Phase 3Recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in erectile dysfunction (ED) (3 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: International Index of Erectile Function - Erectile Function domain score at 12 weeks. Started Oct 2026; status: recruiting.
02
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT07899073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07899073.